53.0581  -0.752 (-1.4%)		01-26 11:08
Open: 52.65 High: 53.69 Volume: 131,009		Pre. Close: 53.81 Low: 51.93 Market Cap: 4,280(M)

Short term
Mid term
Targets	6-month :	67.57	1-year :	78.92
Resists	First :	57.85	Second :	67.57
Pivot price	50.88
Supports	First :	45.17	Second :	37.34
MAs	MA(5) :	54.93	MA(20) :	48.32
	MA(100) :	41.6	MA(250) :	32.07
MACD	MACD :	3.6	Signal :	3.2
%K %D	K(14,3) :	80.9	D(3) :	86.3
RSI	RSI(14): 61.5
52-week	High :	57.85	Low :	14.8

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CGON ] has closed below upper band by 40.4%. Bollinger Bands are 153.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	55.51 - 55.85	55.85 - 56.1
Low:	52.52 - 52.95	52.95 - 53.25
Close:	53.25 - 53.87	53.87 - 54.32

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

Tue, 13 Jan 2026
CG Oncology files amendment to increase stock offering to $550 million By Investing.com - Investing.com South Africa

Tue, 13 Jan 2026
CG Oncology Expands At-The-Market Equity Offering Capacity - TipRanks

Sun, 11 Jan 2026
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene - Seeking Alpha

Mon, 08 Dec 2025
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Yahoo Finance

Fri, 14 Nov 2025
CG Oncology, Inc. (CGON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Wed, 08 Oct 2025
CG Oncology stock initiated Buy at Guggenheim (CGON:NASDAQ) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	-78 (M)
Shares Float	0 (M)
Held by Insiders	8.262e+007 (%)
Held by Institutions	6.544e+007 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	-1.1289e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-2.05
Profit Margin	0 %
Operating Margin	-3 %
Return on Assets (ttm)	68.9 %
Return on Equity (ttm)	-17.6 %
Qtrly Rev. Growth	2.17e+006 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-1.7953e+008 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	-25.95
Price to Sales	0
Price to Cash Flow	0

Dividend	1.292e+007
Forward Dividend	1.371e+007
Dividend Yield	24294800%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.